| Name | Title | Contact Details |
|---|
ALSP Inc. (American Life Science Pharmaceuticals, Inc.), is a privately held company based in San Diego, California, developing new small molecule drugs for treating neurodegenerative disease initially focused on traumatic brain injury and Alzheimer`s disease. Our approach is to identify key enzymes in the brain, called proteases, which produce biologically active peptides, proteins or processes that are thought to underlie the disease. We then use those enzymes as targets for screening compounds that inhibit these proteases and thereby prevent the harmful effect caused by these peptides, proteins and processes to treat the disease. By using this innovative process, our goal is to create and advance highly-effective drug development strategies and products for treating not only traumatic brain injury and Alzheimer`s disease, but other Neurodegenerative Conditions such as Huntington`s disease, Parkinson`s disease and MS, and recover quality of life for those patients and their families.
Miraculins is a pre-revenue biotechnology company that acquires, develops and commercializes new, non-invasive diagnostic and risk assessment tests to aid physicians in the earlier diagnosis of disease. The Company specializes in the development and manufacturing of medical devices and has been successfully accessing capital on the public markets as required to finance its operations to date. It is currently preparing for transition to a commercialization phase. Miraculins began as a research and development company in 2002, with a focus on biomarker discovery. In June of 2008, the company shifted its focus to diagnostic asset development where it began to in-license and acquire diagnostic and risk assessment technologies that had completed early stage research and addressed significant unmet medical needs in the U.S., Canada, and global markets.
We are a biotechnology leader that discovers, develops and delivers innovative therapies to improve the lives of patients with neurodegenerative diseases, hematologic conditions and autoimmune diseases. Patients worldwide benefit every day from our medicines for multiple sclerosis (MS) and hemophilia. Founded in 1978, we are one of the world’s oldest independent biotechnology companies. Our development pipeline is focused on areas of high unmet medical need, as we pursue new therapies for patients suffering from diseases with few or no treatment options. These include programs for secondary progressive MS, Alzheimer’s Disease, spinal muscular atrophy, lupus and amyotrophic lateral sclerosis (ALS), amongst others. With more than 7,500 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.
AltMed LLC is a fully integrated, science-based Florida company bringing compassion, community engagement and pharmaceutical industry precision to the development, production and dispensing of medical cannabis.
Inscripta is a gene-editing technology company dedicated to creating the tools needed to revolutionize how we feed, fuel, and heal humanity.